Skip to main content

Novartis — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

101
Companies
$2.8B
Total invested
$54.3M
Avg. check
20
Industries
Biotechnology 15Health Care 11Therapeutics 8Biopharma 6Medical 5Pharmaceutical 5+14 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 7396 of 101
Hyku
September 2023

Hyku is a biotech company that develops precise covalent targeting of disease-causing proteins.

Biopharma · Lexington$56.0M Seed
Poseida Therapeutics
August 2023

Poseida Therapeutics is a biopharmaceutical company utilizing gene engineering capabilities to develop targeted therapeutics.

Biopharma · San Diego$50.0M Post Ipo Equity
Tagworks Pharmaceuticals
June 2023

Tagworks Pharmaceuticals is a privately held biotech company

Biotechnology · Nijmegen$65.0M Series A
RxLightning
June 2023

RxLightning automates the manual enrollment process of starting a patient on specialty medications.

Information Services · New Albany$17.5M Series A
Amphista Therapeutics
December 2022

Amphista Therapeutics operates as a biopharmaceutical company.

Biopharma · CambridgeSeries B
COTA Healthcare
October 2022

Bringing clarity to cancer. Working to ensure that everyone touched by cancer has a clear path to the right care.

Artificial Intelligence (AI) · New YorkSeries E
Anokion
October 2022

Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance.

Biotechnology · Ecublens$35.0M Series Unknown
Alladapt Immunotherapeutics
August 2022

Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy.

Biotechnology · Menlo Park$50.0M Debt Financing
Arkangel AI
April 2022

Transforming medical data into predictive algorithms without code

Artificial Intelligence (AI) · Montréal$75K Pre-Seed
NuvoAir
January 2022

NuvoAir is a value-based specialty management platform transforming the diagnosis and management of chronic heart and lung conditions.

Health Care · Boston$11.0M Series A
SiO2 Materials Science
December 2021

SiO2 Materials Science is a plastic container designing company.

Manufacturing · Auburn$205.0M Debt Financing
Anaveon
December 2021

Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.

Therapeutics · Bottmingen$119.7M Series B
Pear Therapeutics
December 2021

Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.

Biotechnology · Boston$125.0M Post Ipo Equity
CODA Biotherapeutics
December 2021

CODA Biotherapeutics develops a chemogenetic platform designed to modulate neuronal activity.

Biotechnology · South San Francisco$28.0M Series Unknown
Kedalion Therapeutics
November 2021

Kedalion Therapeutics is a biotechnology company that develops and commercializes transformative topical ophthalmic therapies.

Biotechnology · Menlo ParkSeries B
Dunad Therapeutics
November 2021

Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.

Biotechnology · London$24.0M Series A
Soteria Biotherapeutics
May 2021

Soteria is a biotechnology company that develops immunotherapies to treat cancer patients

Biopharma · San Francisco$42.0M Series A
Ayala Pharmaceuticals
February 2021

Ayala Pharmaceuticals a clinical-stage biopharmaceutical company focused on developing and commercializing small molecule therapeutics.

Biotechnology · Wilmington$25.0M Post Ipo Equity
Aspen RxHealth
January 2021

Aspen RxHealth is a service powered by an app-based platform that connects pharmacists with patients.

Apps · Tampa$23.0M Series B
AccessNow
July 2020

AccessNow is a platform that serves as a go-to resource for accessibility information.

Information Services · Toronto$250K Grant
Arctos Medical
December 2019

Arctos Medical is a developed gene therapy that does not correct rare genetic eye diseases but much more common cases of blindness.

Bern$8.2M Seed
IFM Therapeutics
December 2019

DescriptionIFM Therapeutics is a pharmaceutical company focused on developing biological treatments for autoimmune diseases.

Biopharma · Boston$55.5M Series Unknown
Forendo Pharma
July 2019

Forendo Pharma is a developer of novel drugs intended for the treatment of urological and other endocrinological diseases.

Health Care · Turku$5.6M Series Unknown
Anthos Therapeutics
February 2019

Anthos Therapeutics is a biopharmaceutical company that specializes in the treatment of cardiovascular and metabolic diseases.

Biopharma · Cambridge$250.0M Series A

Where Novartis invests

Biotechnology15
Health Care11
Therapeutics8
Biopharma6
Medical5
Pharmaceutical5

About Novartis's portfolio

How many companies has Novartis invested in?

Novartis has invested in 101 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Novartis invest in?

Novartis's top investment sectors include Biotechnology, Health Care, Therapeutics, Biopharma, Medical. The firm invests across 20 different industry categories.

What is Novartis's largest investment?

Among tracked funding rounds, Anthos Therapeutics received $250.0M in a Series A round. Novartis's total known invested capital is $2.8B.

What is the average investment size for Novartis?

Novartis's average investment size is $54.3M across its portfolio of 101 companies.

What are Novartis's most recent investments?

Recent Novartis portfolio additions include Hyku, Poseida Therapeutics, Tagworks Pharmaceuticals, RxLightning, Amphista Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 101 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →